Lucas Batties
Associate
Lucas Batties is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Lucas is a biologist with technical experience in microbiology and population genetics. He focuses on patent prosecution and intellectual property counseling.
Experience
Lucas Batties is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Lucas is a biologist with technical experience in microbiology and population genetics. He focuses on patent prosecution and intellectual property counseling.
Education
- J.D., Boston University School of Law, 2024
- B.S., Microbiology, California Polytechnic State University, San Luis Obispo, 2020
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., Boston University School of Law, 2024
- B.S., Microbiology, California Polytechnic State University, San Luis Obispo, 2020
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Biological Sciences and Biotechnology
- Cell biology
- Genetics
- Microbiology
Therapeutics and Drug Discovery
- Antimicrobial agents
Diagnostics and Medical Devices
- Diagnostics
- Medical devices
Genomics and Data Analysis
- Next-generation sequencing
- Sequencing
Technical Fluency
Biological Sciences and Biotechnology
- Cell biology
- Genetics
- Microbiology
Therapeutics and Drug Discovery
- Antimicrobial agents
Diagnostics and Medical Devices
- Diagnostics
- Medical devices
Genomics and Data Analysis
- Next-generation sequencing
- Sequencing
Focus Areas
Recent Insights
Client Highlights
Firm Advises Candid Therapeutics on Patent Matters Related to Its $2 Billion Acquisition by UCB
On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Learn More
Client Highlights
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio
On March 2, 2026, Rallybio and Candid Therapeutics, a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction. The combined company expects to operate under the name Candid Therapeutics and trade on Nasdaq under the ticker symbol CDRX. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.